Key Highlights
- Biohaven (NYSE:BHVN) announced on October 8, 2026 a licensing deal with Ono Pharmaceutical worth up to USD 100 million near term: USD 80 million at signing plus a USD 20 million milestone expected within about a year.
- Ono gets rights in Japan, South Korea, Taiwan and ASEAN countries to the MoDE pan-IgG degrader portfolio, BHV-1300, BHV-1310 and BHV-1320, while Biohaven keeps the US, Europe and China.
- Biohaven (NYSE:BHVN) will also receive royalties of roughly 20% of Ono's net sales in the territory, and BHV-1300 is in Phase 3 for Graves' disease.
- In Phase 1, subcutaneous BHV-1300 cut total IgG by up to 87%, and in a Phase 1b Graves' study it reduced the pathogenic TSH receptor autoantibody and normalized free T3 and T4.
The Deal Terms
Biohaven (NYSE:BHVN) and Ono Pharmaceutical signed an agreement on October 8, 2026 giving Ono sole rights to develop and sell Biohaven's extracellular IgG degraders in Japan, South Korea, Taiwan and ASEAN countries. The portfolio includes lead candidate BHV-1300 and follow-on candidates BHV-1310 and BHV-1320. Biohaven receives USD 80 million upfront, a USD 20 million milestone expected within about a year, so up to USD 100 million near term, plus royalties of roughly 20% on Ono's net sales. Chief executive Vlad Coric called Ono the ideal partner, and Ono president Toichi Takino said the company looks forward to advancing the development program. J.P. Morgan and Sullivan & Cromwell advised Biohaven.
How the Drug Works
BHV-1300 is an investigational small molecule built on the MoDE platform, a bispecific design that directs a target toward the liver through the ASGPR receptor so it can be degraded. It targets IgG1, IgG2 and IgG4 while sparing IgG3. In autoimmune disease such as Graves' disease, pathogenic IgG antibodies drive the illness, so lowering them is the goal. Biohaven (NYSE:BHVN) reports Phase 1 reductions in total IgG of up to 87% with subcutaneous dosing, and a Phase 1b Graves' study that normalized free T3 and T4 and improved symptoms. The release did not give Phase 3 design, enrollment or timelines, so the path to approval in Asia remains uncertain. Biohaven also describes other autoimmune indications as under investigation.
Risks and What to Watch
Upfront cash reduces funding risk, but the milestone is the only dated payment, and royalties depend on approvals and sales that are years away. Phase 3 results can disappoint even after encouraging early data, and the release gave no efficacy data from late-stage trials. Regulators in Asia may also set their own requirements, and Ono must fund and run local development before any Royalty arrives. Biohaven (NYSE:BHVN) retains rights outside the territory, so Western outcomes still matter most. Investors should watch for Phase 3 updates, whether other autoimmune indications start trials and how the stock responds. A share price reaction was not verified, and the release was dated October 8, 2026. This is not Investment advice.
Where Things Stand
Biohaven (NYSE:BHVN) gets USD 80 million now, a USD 20 million milestone expected within about a year, and royalties of roughly 20% in Japan, South Korea, Taiwan and ASEAN. That validates the degrader platform commercially and funds development, but it does not remove clinical risk. BHV-1300 is still in Phase 3, and royalty income depends on approval and sales. The balance of evidence is positive on financing and unproven on efficacy. The next catalyst is Phase 3 progress.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...